Geron Announced That The European Medicines Agency Has Validated Imetelstat Marketing Authorization Application For Transfusion-dependent Anemia In Patients With Lower-risk Myelodysplastic Syndromes. The Review Is Expected To Be Approximately 14 Months
Portfolio Pulse from Benzinga Newsdesk
Geron Corporation has announced that the European Medicines Agency has validated its marketing authorization application for Imetelstat, a treatment for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes. The review process is expected to last approximately 14 months.
September 29, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron's Imetelstat has received validation for its marketing authorization application from the European Medicines Agency. This could potentially open up a new market for the drug, pending a successful review process.
The validation of the marketing authorization application for Imetelstat by the European Medicines Agency is a positive development for Geron. It signifies the potential for the drug to be marketed in Europe, pending a successful review process. This could potentially lead to increased revenues for the company, hence the positive score. However, as the review process is expected to last 14 months, the impact may not be immediate.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100